Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P157
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kelly, Ronan J
Chung, Ki
Gu, Yu
Steele, Keith E
Rebelatto, Marlon C
Robbins, Paul B
Tavakkoli, Fatemeh
Karakunnel, Joyson J
Lai, Dominic W
Almhanna, Khaldoun
Article History
First Online: 4 November 2015